Anteris Technologies enters $250M ATM equity offering with TD Cowen to fund DurAVR heart valve development

Anteris Technologies Global Corp.

Entered into Sales Agreement with TD Securities (USA) LLC for at-the-market offering of up to $250M of common stock.
Commission payable to TD Cowen is 3.0% of gross proceeds for sales as agent.
Net proceeds primarily for ongoing development of DurAVR Transcatheter Heart Valve System and working capital.
Sales may be made on Nasdaq, in negotiated transactions, or block trades; company controls timing and size.
Offering terminates upon sale of all shares or either party giving 10 days' notice; shelf effective since Jan 8, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.